Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Watch

NSCLC Brain Metastases Respond to Erlotinib and Radiation

DOI: 10.1158/2159-8290.CD-RW2013-024 Published March 2013
  • Article
  • Info & Metrics
Loading
  • Major finding: Erlotinib plus whole-brain radiotherapy improves survival in NSCLC patients with brain metastases.

  • Concept: EGFR-mutant tumors may be especially prone to brain dissemination.

  • Impact: Concurrent erlotinib and radiotherapy may benefit patients with EGFR-mutant metastatic tumors.

Figure1

For the approximately 20% to 40% of patients with non–small cell lung cancer (NSCLC) who develop brain metastases, the median survival after whole-brain radiotherapy (WBRT) has historically been less than 6 months. Overexpression of EGF receptor (EGFR), which is mutated in 10% to 15% of patients with NSCLC, has been implicated in resistance to radiotherapy, and erlotinib, an EGFR inhibitor that may penetrate the blood–brain barrier, can sensitize cancer cells to radiation in vitro. Welsh and colleagues therefore evaluated the effect of concurrent erlotinib and WBRT on brain metastases arising from NSCLC in a prospective phase II study with endpoints of increased overall survival compared with historical controls, radiologic response, and safety. Patients were unselected for EGFR status, and because erlotinib was not yet standard first-line therapy for NSCLC during the patient enrollment period, previous treatments were limited to systemic chemotherapy or stereotactic radiosurgery. The combination of erlotinib and WBRT was well tolerated, and no grade 4 or 5 adverse effects were observed. The overall response rate was 86% in those assessed for radiologic central nervous system (CNS) response, with 31% of patients experiencing a complete CNS response. Overall survival after concurrent erlotinib and WBRT exceeded that of historical controls, with a median survival of 11.8 months. Of note, the median overall survival was 9.3 months in patients with EGFR–wild-type NSCLC and 19.1 months in patients with EGFR-mutant NSCLC. EGFR mutations were present in 53% of patients, a significantly higher rate than NSCLC in general, raising the possibility that EGFR mutation may be linked to brain dissemination. Although this was a small nonrandomized study and first-line erlotinib usage may lead to different outcomes, these findings suggest that concurrent erlotinib and WBRT may be a safe and effective treatment for brain metastases from NSCLC.

Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non–small-cell lung cancer. J Clin Oncol 2013 Jan 22 [Epub ahead of print].

  • ©2013 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 3 (3)
March 2013
Volume 3, Issue 3
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
NSCLC Brain Metastases Respond to Erlotinib and Radiation
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
NSCLC Brain Metastases Respond to Erlotinib and Radiation
Cancer Discov March 1 2013 (3) (3) OF8; DOI: 10.1158/2159-8290.CD-RW2013-024

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
NSCLC Brain Metastases Respond to Erlotinib and Radiation
Cancer Discov March 1 2013 (3) (3) OF8; DOI: 10.1158/2159-8290.CD-RW2013-024
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Epstein–Barr Virus–Induced Antitumor Immune Response May Be Harnessable
  • FBXO44 Silences Repetitive Elements during DNA Replication in Cancer
  • Cryo-EM Structures Reveal Mechanism of Anticancer MCT1 Inhibitors
Show more Research Watch

Clinical Trials

  • The LSD1 Inhibitor Iadademstat Is Active in Acute Myeloid Leukemia
  • Intermittent Inhibition of BRAF plus MEK Is Not Beneficial in Melanoma
  • Anti–PD-1 plus a VEGFR2 Inhibitor Shows Promise in Cervical Cancer
Show more Clinical Trials
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement